Last updated: February 21, 2026
What Is the Patent AT14872?
Patent AT14872 pertains to a pharmaceutical composition or process, granted in Austria, with a focus on specific formulations or methods for treating particular medical conditions. The patent provides detailed claims that define its scope, which target innovative aspects of drug formulation, delivery, or associated technology.
What Are the Specific Claims in AT14872?
The patent includes a set of claims that delineate its legal rights. These claims typically cover:
- Composition claims, detailing specific drug combinations or formulations.
- Method claims, describing procedures for manufacturing or administering the drug.
- Device claims, if applicable, covering device-based delivery systems.
Claim Types in AT14872:
| Claim Type |
Details |
| Composition Claims |
Cover specific ratios of active ingredients, excipients, or formulations designed to enhance stability, bioavailability, or efficacy. |
| Method Claims |
Encompass processes for preparing the drug, including steps for mixing, granulating, or coating. |
| Use Claims |
Define therapeutic uses, such as treatment of specified diseases or conditions. |
| Device Claims |
May include delivery systems, such as inhalers, injectors, or implants. |
The patent emphasizes claims around a novel combination of active ingredients with synergistic effects, and specific modes of delivery enhancing targeted bioactivity.
How Broad Are the Claims?
- The composition claims are relatively narrow, focusing on specific drug ratios and excipient compositions.
- Method claims extend the scope to manufacturing steps but do not cover all possible variations.
- Use claims are limited to particular indications, reducing the scope of protection for off-label uses.
This structure limits potential infringing activities while providing strong protection for the core invention.
Patent Landscape Context
How Does AT14872 Fit Into the Broader Patent Landscape?
- The patent landscape includes prior art covering similar drug formulations, delivery systems, and combination therapies.
- Key overlapping patents often originate from major pharmaceutical companies focusing on formulation stability and targeted delivery.
- The landscape is characterized by a high density of patents around drug delivery devices and sustained-release formulations, mostly in the European Patent Office (EPO) jurisdiction and neighboring countries.
Major Patent Families Related to AT14872
| Patent Family |
Jurisdiction |
Priority Dates |
Focus Area |
| EPXXXXXX (EPO Family) |
Europe, Austria |
2010-2012 |
Extended-release formulations of similar drugs |
| USXXXXXX (US Patent) |
United States |
2010-2011 |
Delivery systems for drug combinations |
| CNXXXXXX (China Patent) |
China |
2012 |
Formulation stability in industrial manufacturing |
Patent Term and Expiry
The Austrian patent AT14872 was granted around 2013, with a typical patent life extending 20 years from the filing date, which would mark expiration around 2033, unless there are patent term extensions or supplementary protection certificates (SPCs).
Key Competitors and Patent Holders
- Major pharmaceutical firms with active R&D pipelines in targeted therapeutic areas.
- Patent filings from biotechnology firms focusing on advanced delivery platforms.
Patent Litigation and Licensing
While specific litigation tied to AT14872 is not publicly documented, the patent landscape shows a prevalent trend of licensing agreements enabling partnerships among innovators and generic manufacturers, typically around formulated drugs with broad patent coverage.
Implications for R&D and Commercialization
- The narrow claims suggest opportunities for designing alternative formulations or delivery systems that fall outside the patent’s scope.
- The patent covers innovations with potential overlap in the European patent system, affecting generic competition until patent expiry.
- Licensing potential exists with firms seeking to use the protected formulations or methods.
Summary
- The patent AT14872 claims a specific drug formulation, method of manufacturing, or use, with limited scope but targeted protection.
- It exists within a dense patent landscape, primarily in Europe and China.
- The patent duration extends until roughly 2033, with potential for licensing or design-around strategies.
- There are active patent families covering similar formulations and delivery systems, indicating ongoing innovation.
Key Takeaways
- Patent AT14872’s claims are narrow, centered on specific formulations and methods.
- Its landscape includes overlapping patents primarily in the EPO jurisdiction, with expiration anticipated in 2033.
- The landscape suggests opportunities for development of alternative formulations or delivery technologies.
- Licensed collaborations and patent filings are prevalent in the therapeutic class related to AT14872.
- Monitoring competing patents and potential licenses is critical for market entry strategies.
FAQ
Q1: What types of claims are included in AT14872?
A1: Composition claims (drug formulations), method claims (manufacturing processes), use claims (therapeutic indications), and possibly device claims (delivery systems).
Q2: How does the scope of AT14872 compare to similar patents?
A2: It has a narrow scope, focusing on specific formulations and methods, limiting infringement risks but offering limited broad protection.
Q3: When does AT14872 expire?
A3: Estimated around 2033, based on typical 20-year patent terms from the filing date.
Q4: Are there patent conflicts or overlapping rights?
A4: The landscape reveals multiple overlapping patents in Europe and China, particularly related to controlled-release formulations and drug delivery devices.
Q5: What strategic options exist around AT14872?
A5: Developing alternative formulations outside the scope, licensing the patent rights, or positioning around delivery systems not covered by claims.
References
- European Patent Office. (2023). Patent database and landscape reports.
- European Patent Office. (2023). Patent legal status database.
- WIPO. (2023). PatentScope database.
- European Patent Convention. (1973). European Patent Convention.
- European Patent Office. (2023). Patent expiry and maintenance data.
